Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen you stop taking Mounjaro, the medicine clears from your body over several weeks, appetite typically returns, and most people regain a significant portion of the weight they lost. This is not a failure of willpower. Tirzepatide works by activating gut-hormone receptors that suppress appetite; once those signals are removed, your body reverts to its previous hunger patterns. These are prescription-only medicines that require ongoing clinical assessment, and a prescriber is the right person to discuss whether, when, or how to stop. The NHS patient information for tirzepatide covers what to expect and when to seek advice.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide's half-life is roughly five days, which means blood levels fall by half every five days after your final injection. Within three to four weeks, the concentration has dropped to a point where its effect on appetite and gastric emptying is substantially reduced. Your stomach empties at its previous, faster pace. Food moves through more quickly, and the fullness signals that made smaller portions feel satisfying gradually quieten.
Hunger hormones, including ghrelin, begin reasserting themselves. For many people this feels like appetite returning with a snap, not a gentle dial turning up, but a more sudden awareness of hunger at mealtimes and between them. This is the biology, not a personal failing. Mounjaro was holding a hormonal lever in place; removing it lets the lever return to its original position.
Blood sugar regulation may also shift if you have type 2 diabetes or insulin resistance, because tirzepatide improves both conditions via its dual GIP and GLP-1 receptor action. Stopping may see fasting glucose and post-meal spikes creep back toward baseline, which is another reason to have this conversation with a prescriber rather than simply not reordering. If you want a full picture of what happens to your body after Mounjaro before considering a break, the Mounjaro injection guide covers the mechanism in more detail.
This is what most people asking this question really want to know. The evidence is clear: for the majority of people who stop, meaningful weight regain happens. NICE's appraisal of tirzepatide (TA1026) acknowledged that obesity is a chronic condition and that ongoing treatment is the model that maintains results, precisely because weight tends to return when medicine stops.
The rate varies. Some people regain weight within three months; others find it takes closer to a year before they are back near their starting point. Variables include how long treatment lasted, how much weight was lost, whether lifestyle changes are embedded, and individual metabolic factors. Regain tends to be gradual at first, then faster as hunger normalises fully.
It is worth noting that the lifestyle changes made during treatment (smaller portion habits, a preference for protein, routine activity) can slow regain meaningfully, even if they do not prevent it entirely. Treatment puts the work in the right context; stopping removes the pharmacological support, but the habits built alongside it still matter. Our dedicated page on what happens when you stop taking Mounjaro for weight loss goes into this in more detail. You can also explore what stopping Mounjaro means specifically for long-term weight loss in more detail on a dedicated page.
A reasonable concern, and the short answer is: generally not. The gastrointestinal side effects that trouble some people at the start of Mounjaro (nausea, loose stools, reduced appetite to the point of discomfort) are linked to rising drug levels and dose escalation steps, not to the presence of the medicine at steady state. Stopping does not trigger a surge in drug levels; it triggers a fall. So nausea on stopping is not common.
What some people do notice is a temporary sense of heightened hunger that feels uncomfortable precisely because it contrasts with months of reduced appetite. That can be distressing, but it is physiological and typically settles as the body readjusts over several weeks.
Injection-site effects, of course, simply stop. The pen that lived in the fridge door alongside the butter and the milk is gone, and with it the weekly routine. For many people the structure of a weekly injection had become part of how they managed eating patterns, so losing that cue is a practical adjustment as much as a physical one. If you have questions about what to expect across the full arc of treatment, the Mounjaro FAQs address many of the questions our prescribers hear regularly.
If you stopped and are thinking about restarting, or are weighing whether to continue, speaking to a prescriber is the straightforward next step. There is also useful context on what happens when you stop using Mounjaro and on the broader picture of stopping across our clinical content. For anyone considering a private route to treatment, checking your eligibility through a free consultation is the place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.